- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01160471
Noninvasive Imaging of Heart Failure: A Pilot Study
Noninvasive Imaging of Heart Failure
Background:
- Heart failure is a common cardiovascular disorder whose incidence increases with age, affecting up to 10% of people older than 65 years of age. As the population ages, the prevalence and cost of heart failure will continue to rise. Researchers are interested in using noninvasive imaging methods to better understand the symptoms and effects of heart failure.
Objectives:
- To conduct a noninvasive comparative imaging study of individuals with heart failure.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with heart failure (with at least mild symptoms and slight limitations on physical activity).
Design:
- This study will last approximately 2 years and will require four visits to the National Institutes of Health Clinical Center, with one screening visit and three study visits.
- Participants will be screened with a full medical history and physical examination, as well as blood and urine samples.
- Participants will have the following tests during each study visit:
- Physical examination
- Blood and urine samples
- Cardiac magnetic resonance imaging
- Cardiac computerized tomography to study the blood vessels in and leading to the heart
- Echocardiogram to evaluate heart function
- Electrocardiogram to measure heart electrical activity
- The three study visits will take place 1 year apart. Participants will also receive follow-up phone calls 6 months after the first and second visits.
- No treatment will be provided as part of this protocol.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
The common inclusion criteria between patients and controls are:
A. Able to understand and sign informed consent.
B. Able to complete a MRI or CT scan.
C. Age greater than or equal to 18 years old.
Heart Failure subject:
D. Men and women with a clinical diagnosis of heart failure.
E. New York Heart Association functional class II or worse.
F. For the normal ejection fraction arm.
- Preserved left ventricular ejection fraction (EF >50%)
Diastolic dysfunction defined one or more of the following
- LVEDP > 16 mm Hg
- PCW > 12 mm Hg
- E/E ratio >15
- E/E ratio >8 AND NT-proBNP >220 pg/mL
For the systolic dysfunction arm:
Left ventricular ejection fraction <40%
Normal Control:
G. Men and women without a clinical diagnosis of heart failure.
H. NIH employees may be involved and NIH requirements will be followed as laid out in NIH Policy Manual 2300-630-3 - Leave Policy For NIH Employees Participating In NIH Medical Research Studies.
EXCLUSION CRITERIA:
Individuals will be excluded from the study if they are discovered to have coexistent conditions that may contribute to structural or functional cardiac abnormalities, which may confound interpretation of results, are ineligible for MRI or if they are at increased risk for Nephrogenic Systemic Fibrosis (NSF) including:
A. Contra indications for gadiolinium-based contrast agent:
- eGFR < 30ml/min/1.73m(2)
- Acute renal failure, renal transplantation, current dialysis treatment or hepatorenal syndrome
- History of liver transplantation or severe liver disease
- Severe Asthma
- Hemoglobinopathies, sickle cell anemia and thalassemias major
- History of multiple myeloma
- History of significant allergic reaction to gadolinium-based contrast agents
B. Medical conditions associated with increased collagen turnover which may confound interpretation of biomarkers of collagen synthesis. Examples include systemic amyloid disease, cirrhosis, liver, pulmonary, or renal fibrosis, inflammatory states, cancer, recent trauma or surgery;
C. Pregnant or lactating women;
D. Mental, neurologic or social condition preventing understanding of the rationale, procedures, risks and potential benefits associated with the trial;
E. Any other conditions that precludes safety for MRI or MDCT per the researcher s evaluation.
F. Patients otherwise eligible but with any of the following contraindications for iodine-based CT contrast agent will be excluded from contrast CT angiography but may undergo all other study procedures:
- Renal dysfunction (defined as eGFR <45 mL/min/m(2))
- Current clinical diagnosis of renal failure
- Prior hypersensitivity to iodine containing substances (shellfish, iodine, and or previous contrast reactions to contrast agents.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Healthy Volunteers
Adult men and women without a clinical diagnosis of heart failure
|
Patients
Adult men and women with a clinical diagnosis of heart failure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post contrast myocardial T1 measured by CMR.
Time Frame: Study end
|
The primary aim of this protocol is to investigate noninvasive imaging methods for quantifying diffuse myocardial fibrosis with cardiac magnetic resonance imaging(CMR) in heart failure patient
|
Study end
|
Collaborators and Investigators
Investigators
- Principal Investigator: Elizabeth C Jones, M.D., National Institutes of Health Clinical Center (CC)
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 100153
- 10-CC-0153
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MRI
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
PfizerCompletedMRI SedationUnited States, Japan
-
University of UtahWithdrawnMRI ScansUnited States
-
SpinTech, Inc.University of Iowa; University of Texas Southwestern Medical Center; Loma Linda... and other collaboratorsCompleted
-
Rennes University HospitalRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of LiegeUnknown